Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage
Key facts
- Who runs it
- Beijing Tiantan Hospital
- Where
- China41 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 1,192 people, planned
- Started
- 2 Apr 2026
- Expected to end
- Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Minocycline hydrochloride capsules
- Placebo capsules of Minocycline hydrochloride capsules
- Record updated
- 23 April 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- CT-confirmed spontaneous supratentorial intracerebral hemorrhage
- Aged 18 to 80 years
- Within 48 hours of symptom onset
- Hematoma volume 15-40 ml
- NIHSS score 8-24, with item 1a ≤ 2
- Signed informed consent by the patient or legal representative
Who cannot take part
- Intracranial or spinal surgery within the past 3 months
- Any major surgery or severe physical trauma within the past month
- Secondary intracerebral hemorrhage (traumatic, tumor-related, vascular malformation, aneurysm, coagulation disorder, etc.)
- Intraventricular hemorrhage filling one entire lateral ventricle, third ventricle, or fourth ventricle, or more than half of two lateral ventricles
- Significant subarachnoid hemorrhage (Fisher grade ≥ 3) or subdural hemorrhage
- Patients with uncontrollable hypertension ( systolic blood pressure persistently ≥ 180 mmHg despite intensive antihypertensive treatment)
- Progressive neurological or other severe systemic diseases
- Planned surgical intervention for the intracerebral hemorrhage
- Pre-stroke disability (modified Rankin Scale score > 1)
- Allergy or intolerance to minocycline or other tetracycline antibiotics
- History of pseudomembranous enteritis or antibiotic-associated enteritis
- Other conditions that are not suitable for participating in this clinical trial, such as inability to understand and/or follow the research procedures due to mental, cognitive, emotional, or physical disorders, etc
- Severe cardiac insufficiency (NYHA Class III-IV), severe liver disease (ALT or AST > 3 times the normal upper limit value), severe renal insufficiency (serum creatinine > 2 times the normal upper limit value, or glomerular filtration rate < 45 ml/min), or malignancy with life expectancy < 1 year
- Moderate to severe anemia (hemoglobin < 90 g/L), thrombocytopenia (platelet count < 100×10\^9/L), leukopenia (white blood cell count < 2×10\^9/L), or coagulopathy (INR > 1.5)
- Use of tetracycline antibiotics within the past week
- Females who are pregnant, within 30 days postpartum, or in the lactation period
- Participated in other interventional clinical trials within the past 3 months
- Inability to obtain signed informed consent from the patient or representative
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. It aims to evaluate the efficacy and safety of oral minocycline in patients with acute spontaneous intracerebral hemorrhage within 48 hours of onset.
The 2 groups in the trial
- Active Comparator: Minocycline treatment groupTreatment being tested
Minocycline Hydrochloride Capsules (50 mg per capsule). The first dose (200mg, 4 capsules) should be given immediately after randomization (within 30 minutes); Subsequently, 100mg (2 capsules) will be administered once every 12 hours; a total of 10 times (lasting 5 days; the subject with dysphagia will be administrated through a nasal feeding tube).
Treatment: Minocycline hydrochloride capsules
- Placebo Comparator: Minocycline placebo-control groupPlacebo, for comparison
Placebo of Minocycline Hydrochloride capsules (50mg per capsule, containing 0 mg of Minocycline). The method of administration was the same as that of treatment group.
Treatment: Placebo capsules of Minocycline hydrochloride capsules
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Minocycline in Patients With Acute Spontaneous Intracerebral Hemorrhage: A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase III Trial
- Criteria questions
- Built from NCT07338175, who can take part
- Record updated
- 23 April 2026